Diagnosis and therapy for pituitary tumors

Current Opinion in Oncology

Volumn 11, Issue 1, 1999, Pages 27-31

  Veznedaroglu, Erol ^a   Armonda, Rocco A ^a   Andrews, David W ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE;

ACROMEGALY; CANCER DIAGNOSIS; COST EFFECTIVENESS ANALYSIS; CUSHING DISEASE; DIAGNOSTIC VALUE; GENE THERAPY; HUMAN; HYPOPHYSIS ADENOMA; PRIORITY JOURNAL; PROLACTINOMA; REVIEW;

ACROMEGALY; ADENOMA; CLINICAL TRIALS; CUSHING SYNDROME; HUMANS; MICROSURGERY; PITUITARY NEOPLASMS;

EID: 0032997450     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199901000-00007     Document Type: Review

References (59)

1. 1 Burkey BB, Speyer MT, Maciunas RJ, Fitzpatrick JM, Galloway RL Jr, Allen GS: Sublabial transseptal, transsphenoidal approach to the pituitary region guided by the ACUSTAR 1 system. Otolaryngol Head Neck Surg 1998, 118:191-194.
2. 2 Marro B, Zouaoui A, Sahel M, Crozat N, Gerber S, Sourour N, et al.: MRI of pituitary adenomas in acromegaly. Neuroradiology 1997, 39:394-399.
3. 3 Manfre L, Midiri M, Rosato F, Janni A, Lagalla R: Perfusion MRI in normal and abnormal pituitary gland: a preliminary study. Clin Imaging 1997, 21:311-318.
4. 4 Magnaldi S, Frezza F, Longo R, Ukmar M, Razavi IS, Pozzi-Mucelli RS: Assessment of pituitary microadenomas: comparison between 2D and 3D MR sequences. Magn Reson Imaging 1997, 15:21-27.
5. 5 Klibanski A, Zervas N: Diagnosis and management of hormone-secreting pituitary adenomas. N Engl J Med 1991, 324:822-831.
6. 6 King JT, Justice AC, Aron DC: Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab 1997, 82:3625-3632. This is a good review of the current workup of incidental pituitary microadenomas. The authors present a cost-effective protocol.
7. 7 Weinstein J, Isaacs S, Shore D, Lewis BS: Diagnosis and management of pituitary tumors. Compr Ther 1997, 23:594-604. This is an excellent review of pituitary tumors, including physical diagnosis and treatments. The authors also describe detailed pharmacologic treatments, including potential side effects of these medications.
8. 8 Buatti JM, Marcus RB: Pituitary adenomas: current methods of diagnosis and treatment. Oncology 1997, 11:791-796.
9. 9 Yeh PJ, Chen JW: Pituitary tumors: surgical and medical management. Surg Oncol 1997, 6:67-92.
10. 10 Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, et al.: Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991, 325:897-905.
11. 11 Yamamoto Y, Davis D, Nippoldt T, Young W, Huston J, Parisi J: False-positive petrosal sinus sampling in the diagnosis of Cushing's disease. J Neurosurg 1995, 83:1087-1091.
12. 12 Young J, Deneux C, Grino M, Oliver C, Chanson P, Schaison G: Pitfall of petrosal sinus sampling in a Cushing's syndrome secondary to ectopic adrenocorticotropin-corticotropin releasing hormone. J Clin Endocrinol Metab 1998, 83:305-308.
13. 13 Heppner C, Becker K, Saeger W, Gunther RW, Allolio B, Krone W, Winkelmann W: Occult eutopic Cushing's syndrome-failure of simultaneous bilateral petrosal sinus sampling to diagnose pituitary-dependent Cushing's syndrome. Eur J Endocrinol 1997, 137:74-78.
14. 14 Popa GT, Fielding V: A portal circulation from the pituitary and the hypothalamic region. J Anat 1930, 65:88-91.
15. 15 Popa GT, Fielding V: The vascular link between the pituitary and the hypothalamus. Lancet 1930, 2:238-240.
16. 16 Bergland RM, Page RB: Can the pituitary secrete directly to the brain? (affirmative anatomical evidence). Endocrinology 1978, 102:1325-1338.
17. 17 Mezey E, Palkovits M, deKloet ER, Verhoef J, deWied D: Evidence for pituitary-brain transport of a behaviorally potent ACTH analog. Life Sci 1978, 22:831-838.
18. 18 Molitch ME: Pituitary incidentalomas. Endocrinol Metab Clin North Am 1997, 26:725-740. This outstanding review of piuitary incidentalomas presents details of pituitary masses. A good description of diagnostic workup, including recommendations, is provided.
19. 19 Scheithauer BW, Sano T, Kovacs KT, Young WFJ, Ryan N, Randall RV: The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 1990, 65:461-474.
20. 20 Marin F, Kovacs KT, Scheithauer BW, Young WFJ: The pituitary gland in patients with breast carcinoma: a histologic and immunohistochemical study of 125 cases. Mayo Clin Proc 1992, 67:949-956.
21. 21 Sano T, Kovacs KT, Scheithauer BW, Young WFJ: Aging and the human pituitary gland. Mayo Clin Proc 1993, 68:971-977.
22. 22 Midgette A, Aron D: High-dose dexamethasone suppression testing versus inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome: a decision analysis. Am J Med Sci 1995, 309:162-170.
23. 23 Tindall GT, Khajavi M, Christy JH, Blevins LS: Natural history of treated Cushing's disease due to pituitary macroadenomas. In Pituitary Adenomas: From Basic Research to Diagnosis and Therapy. Edited by von Werder K, Fahlbusch R. Amsterdam BV: Elsevier Science; 1996:183-187.
24. 24 Blevins LS, Christy JH, Khajavi M, Tindall GT: Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 1998, 83:63-67.
25. 25 Ezzat S: Acromegaly. Endocrinol Metab Clin North Am 1997, 26:703-723. This article provides an exhaustive review with concise outline of acromegaly, including its diagnosis and treatment. There is an excellent review of growth hormone sampling and diagnostic modalities and their explanations.
26. 26 Fahlbusch R, Honegger J, Buchfelder M: Evidence supporting surgery as treatment of choice for acromegaly. J Endocrinol 1997, 155(suppl 1):S53-S55.
27. 27 Melmed S: Acromegaly. N Engl J Med 1990, 322:966-977.
28. 28 Bates AS, Van't Hoff W, Jones JM, Clayton RN: An audit of outcome of treatment in acromegaly. QJM 1993, 86:293-299.
29. 29 van Lindert E, Hey O, Boecher-Schwartz H, Perneczy A: Treatment results of acromegaly as analyzed by different criteria. Acta Neurochir 1997, 139:905-912.
30. 30 Shimon I, Melmed S: Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 1997, 155(suppl 1 ):S3-S6. This is an excellent, detailed article on somatostatin receptors involved in pituitary tumors.
31. 31 Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S: Somatostatin receptor (SSTR) subtype-selective analogues differently suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functional pituitary tumors. J Clin Invest 1997, 100:2386-2392.
32. 32 Arosio M, Macchelli S, Rossi C, Casati G, Biella O, Faglia G: Effects of treatment with octreotide in acromegalic patients: multicenter Italian study. Eur J Endocrinol 1995, 133:430-439.
33. 33 Saitoh Y, Arita N, Ohnishi T, Ekramullah S, Takemura K, Hayakawa T: Absence of apoptosis in somatotropinomas treated with octreotide. Acta Neurochir 1997, 139:851-856.
34. 34 Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. N Engl J Med 1994, 331:904-909.
35. 35 Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al.: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996, 81:2338-2343.
36. 36 Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, et al.: Treatment of macro prolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxford) 1997, 46:409-413.
37. 37 Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al.: Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998, 83:374-378.
38. 38 Merola B, Colao A, Rossi E, La Tessa G, Spaziante R, Lombardi G: Hormonal gradients between inferior petrosal sinuses in various pituitary diseases. Acta Endocrinol 1992, 126:419-424.
39. 39 Molitch ME: Prolactin. In The Pituitary. Edited by Melmed S. Ann Arbor, MI: Blackwell Science; 1995: 136-186.
40. 40 Molitch ME: Prolactinoma. In The Pituitary. Edited by Melmed S. Ann Arbor, MI: Blackwell Science; 1995: 443-477.
41. 41 Loh KC, Shlossberg AH, Ritmaster RS, Holness RO: Giant prolactinomas: a retrospective review. Endocrinology 1996, 6:257-263.
42. 42 Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, et al.: Long term treatment with cabergoline, a new long-lasting ergoline derivative, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 1997, 20:547-551.
43. 43 Colao A, Di Sarno A, Landi ML: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997, 82:3574-3579.
44. 44 Arguello C, Blevins LS: Prolactinomas: diagnosis and management. Contemp Neurosurg 1995, 17:13.
45. 45 Jameson JL, Klibanski A, Black PM, Zervas NT, Lindell CM, Hsu DW, et al.: Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. J Clin Invest 1987, 80:1472-1478.
46. 46 Asa SL, Gerrie BM, Singer W, Horvath E, Kovacs K, Smyth HS: Gonadotropin-secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab 1986, 62:1011-1019.
47. 47 Anyaoku VN, Wood DF, Pavlou R, Williams P, Tan K, Fidler S, Johnston DG: An enzyme-linked immunoadsorbent assay for human pituitary glycoprotein free alpha subunit: evaluation and initial experience in patients with pituitary disease. J Endocrinol 1993, 136:511-516.
48. 48 Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM, Snyder PJ: Recognition of gonadotroph adenoma in women. N Engl J Med 1991, 324:589-594.
49. 49 McCord MW, Buatti JM, Fennell E, Mendenhall WM, Marcus RB Jr, Rhoton AL, et al.: Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 1997, 39:437-444.
50. 50 Witt TC, Kondziolka D, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pituitary tumors. In Radiosurgery 1995. Edited by Kondziolka D. Basel: Karger; 1996:55-65.
51. 51 Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ: Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1994, 30:557-565.
52. 52 Grigsby PW, Simpson JR, Emami BN, Fineberg BB, Schwartz HG: Prognostic factors and results of surgery and postoperative irradiation in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 1989, 16:1411-1417.
53. 53 Coke C, Andrews DW, Corn BW, Werner-Wasik M, Downes B, McCune C, Curran WJ: Multiple fractionated stereotactic radiotherapy of residual pituitary macroadenomas: initial experience. Stereotact Funct Neurosurg 1997, 69:183-190.
54. 54 McNicol AM: Gene expression in pituitary adenomas: new insights. Microsc Res Tech 1997, 39:182-193.
55. 55 Lloyd RV, Osamura RY: Transcription factors in normal and neoplastic pituitary tissues. Microsc Res Tech 1997, 39:168-181.
56. 56 Thapar K, Kovacs K, Stefaneanu L, Scheithauer B, Killinger DW, Lioyd RV, et al.: Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. Am J Pathol 1997, 151:769-784.
57. 57 Oho C, Seino S, Takahashi M: Expression and complex formation of soluble N-ethyl-maleimide-sensitive factor attachment protein (SNAP) receptors in clonal rat endocrine cells. Neurosci Lett 1995, 1986:208-210.
58. 58 Aguado F, Majo G, Ruiz-Montasell B, Canals JM, Casanova A, Marsal J, Blasi J: Expression of synaptosomal-associated protein SNAP-25 in endocrine anterior pituitary cells. Eur J Cell Biol 1996, 69:351-359.
59. 59 Majo G, Ferrer I, Marsal J, Blasi J, Aguado F: Immunocytochemical analysis of the synaptic proteins SNAP-25 and Rab3A in human pituitary adenomas: overexpression of SNAP-25 in the mammosomatotroph lineages. J Pathol 1997, 183:440-446.